HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Vries, E. F.J. Articles by Vaalburg, W. Search for Related Content PubMed PubMed Citation Articles by de Vries, E. F.J. Articles by Vaalburg, W.

Synthesis and In Vivo Evaluation of ¹⁸F-Desbromo-DuP-697 as a PET Tracer for Cyclooxygenase-2 Expression

PET Center, Groningen University Hospital, Groningen, The Netherlands

Cyclooxygenase-2 (COX-2) overexpression has been observed in various pathologies, such as inflammation, cancer, ischemia, and Alzheimer’s disease. As an initial step toward a noninvasive PET technique to assay COX-2 expression, this study describes the synthesis and preliminary evaluation of the radiolabeled COX-2 inhibitor ¹⁸F-desbromo-DuP-697. Methods: Desbromo-DuP-697 was radiolabeled by a nucleophilic aromatic substitution reaction of the nitro precursor with ¹⁸F-fluoride. Biodistribution studies of the tracer were performed in a carrageenan-induced hyperalgesia rat model. Brain uptake was investigated with autoradiography. To confirm the results of the biodistribution, COX activity was determined by a peroxidase assay. Results: Biodistribution studies showed specific binding of the tracer to COX-2 in heart, kidney, brain, and blood cells, but not in the inflamed paw, which was probably due to low COX-2 expression. In the brain, regional differences in tracer uptake were observed, with high uptake in cortical regions. ¹⁸F-Desbromo-DuP-697 did not show any binding to COX-1. Nonspecific uptake was high in fat and intestines. Conclusion: Because of its ability to cross the blood-brain barrier, ¹⁸F-desbromo-DuP-697 appears to be suitable for COX-2 imaging in the brain. Its high nonspecific uptake in the intestines may limit its use for imaging in the abdominal region.

Key Words: PET • desbromo-DuP-697 • cyclooxygenase-2 • inflammation • carrageenan

This article has been cited by other articles:

				R. Goland, M. Freeby, R. Parsey, Y. Saisho, D. Kumar, N. Simpson, J. Hirsch, M. Prince, A. Maffei, J. J. Mann, et al. 11C-Dihydrotetrabenazine PET of the Pancreas in Subjects with Long-Standing Type 1 Diabetes and in Healthy Controls J. Nucl. Med., March 1, 2009; 50(3): 382 - 389. [Abstract] [Full Text] [PDF]

				S. Biswal, D. L. Resnick, J. M. Hoffman, and S. S. Gambhir Molecular Imaging: Integration of Molecular Imaging into the Musculoskeletal Imaging Practice Radiology, September 1, 2007; 244(3): 651 - 671. [Abstract] [Full Text] [PDF]

				L. Johansson, A. Rytkonen, H. Wan, P. Bergman, L. Plant, B. Agerberth, T. Hokfelt, and A.-B. Jonsson Human-Like Immune Responses in CD46 Transgenic Mice J. Immunol., July 1, 2005; 175(1): 433 - 440. [Abstract] [Full Text] [PDF]